natgillin/translations-raw huggingface dataset:
METHOD AND ROUTE(S) OF ADMINISTRATION For intravenous use. 
POSTOPEK IN POT(I) UPORABE ZDRAVILA za intravensko uporabo.
This is equivalent to 0.017% of the recommended maximum daily dietary intake of sodium for an adult. 
To je enako 0,017 % priporočenega največjega dnevnega vnosa natrija s hrano za odrasle osebe.
If patients experience treatment-related symptoms affecting their vision and/or ability to concentrate and react, it is recommended that they do not drive or use machines until the effect subsides. 
Če se bolnikom pojavijo z zdravilom povezani simptomi, ki vplivajo na vid in/ali sposobnost koncentracije in reagiranja, je priporočljivo, da ne vozijo in ne upravljajo strojev, dokler učinek ne mine.
• Compared with patients who did not develop antibodies, no relationship between the presence of anti-panitumumab antibodies and pharmacokinetics, efficacy and safety has been observed. 
• V primerjavi z bolniki, pri katerih se protitelesa niso razvila, niso ugotovili povezanosti med prisotnostjo protiteles proti panitumumabu ter farmakokinetiko, učinkovitostjo in varnostjo.
Patients should be informed of the possibility of a late onset reaction and instructed to contact their physician if symptoms of a hypersensitivity reaction occur. 
Bolnike je potrebno opozoriti na možnost reakcij s poznim nastankom in jim naročiti, naj se obrnejo na svojega zdravnika, če se jim pojavijo simptomi preobčutljivostne reakcije.
Overall, the safety profile of panitumumab was similar to that of cetuximab, in particular regarding skin toxicity. 
V celoti je bil varnostni profil panitumumaba podoben temu, ki ga je imel cetuksimab, zlasti v zvezi s kožno toksičnostjo.
Vectibix is intended for single use only. 
Zdravilo Vectibix je namenjeno samo za enkratno uporabo.
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6. 
Zdravila ne smete mešati z drugimi zdravili razen s tistimi, ki so omenjena v poglavju 6.6. 6.3 Rok uporabnosti
Prolonged exposure to the sun can make the rash worse. 
Podaljšano izpostavljanje soncu zpuščaje lahko še poslabša.
The major study objective was comparison of PFS in the oxaliplatin cohort. 
Glavni cilj študije je bila primerjava PFS v kohorti z oksaliplatinom.
When prepared according to the instructions given in section 6.6, the final panitumumab concentration should not exceed 10 mg/mL. 
Če je zdravilo pripravljeno po navodilih, navedenih v poglavju 6.6, končna koncentracija panitumumaba ne sme preseči 10 mg/ml.
As monotherapy: 
Kot monoterapija:
BRAF mutations in exon 15 were found to be prognostic of worse outcome. 
Mutacije BRAF v eksonu 15 so se izkazale kot napovednik slabšega izida.
Contact lens use is also a risk factor for keratitis and ulceration. 
Poleg tega je uporaba kontaktnih leč dejavnik tveganja za keratitis in razjedo.
There have been reports of overdose at doses up to approximately twice the recommended therapeutic dose (12 mg/kg). 
Opisani so primeri prevelikega odmerjanja v odmerkih do približno dvakratnega priporočenega terapevtskega odmerka (12 mg/kg).
MARKETING AUTHORISATION NUMBER(S) EU/1/07/423/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/07/423/001
Panitumumab + FOLFIRI Wild-type RAS (n = 69) 
Panitumumab in FOLFIRI Divji tip RAS (n = 69)
RAS mutational status should be determined using a validated test method by an experienced laboratory (see section 4.2). 
Mutacijsko stanje RAS mora ugotoviti izkušen laboratorij z uporabo validirane testne metode (glejte poglavje 4.2).
Based on your age (older than 65 years) or general health, your doctor will discuss with you your ability to tolerate taking Vectibix with your chemotherapy treatment. 
Zdravnik se bo, glede na vašo starost (starejši od 65 let) ali splošno zdravstveno stanje, z vami pogovoril o vaši sposobnosti za prenašanje zdravila Vectibix skupaj s kemoterapijo.
Mutant RAS (n = 74) 
Mutantni RAS (n = 74)
If you experience severe diarrhoea please tell your doctor or nurse since you may lose a lot of water from your body (become dehydrated) and this could damage your kidneys. 
Če se vam pojavi huda driska, obvestite svojega zdravnika ali medicinsko sestro, saj zaradi tega lahko izgubite veliko vode iz svojega telesa (postanete dehidrirani) kar lahko poškoduje vaša ledvica.
EGFR is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including EGFR (HER1/c-ErbB-1), HER2, HER3, and HER4. 
EGFR je transmembranski glikoprotein; spada v podskupino tipa I receptorskih tirozin-kinaz, ki vključujejo EGFR (HER1/c-ErbB-1), HER2, HER3 in HER4.
• if you are allergic to panitumumab or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na panitumumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
Dermatologic reactions and soft tissue toxicity 
Dermatološke reakcije in toksičnost mehkih tkiv
What Vectibix is and what it is used for 
Kaj je zdravilo Vectibix in za kaj ga uporabljamo
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Izdaja zdravila je le pod omejenimi pogoji in na recept (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
If these levels are too low, your doctor may prescribe you appropriate supplements. 
Če bodo te koncentracije prenizke, vam bo zdravnik morda predpisal ustrezne dodatke k prehrani.
A trend towards worse survival was also observed with panitumumab in the irinotecan cohort regardless of KRAS mutational status. 
Trend k slabšemu preživetju je bil s panitumumabom opažen tudi v irinotekanski kohorti, ne glede na mutacijsko stanje KRAS.
The European Medicines Agency has waived the obligation to submit the results of studies with Vectibix in all subsets of the paediatric population in colorectal cancer (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Vectibix za vse skupine pediatrične populacije pri kolorektalnem raku (za informacije o pediatrični uporabi glejte poglavje 4.2).
See section 2 “Vectibix contains sodium”. 
Glejte poglavje 2 "Zdravilo Vectibix vsebuje natrij".
427 (92%) patients were evaluable for KRAS status of which 184 had mutations. 
Za oceno statusa KRAS je bilo primernih 427 (92 %) bolnikov; 184 od teh jih je imelo mutacije.
Vectibix could affect your unborn baby or ability to stay pregnant. 
Zdravilo Vectibix lahko neugodno vpliva na nerojenega otroka ali na zmožnost za ohranitev nosečnosti.
EGFR has been implicated in the control of prenatal development and may be essential for normal organogenesis, proliferation, and differentiation in the developing embryo. 
EGFR je domnevno vpleten v nadzor prenatalnega razvoja in je morda nujen za normalno organogenezo, proliferacijo in diferenciacijo razvijajočega se zarodka.
Dilute in a total volume of 100 mL. 
Razredčite v skupni količini 100 ml.
EGFR promotes cell growth in normal epithelial tissues, including the skin and hair follicle, and is expressed on a variety of tumour cells. 
EGFR spodbuja rast celic v normalnih epitelijskih tkivih, vključno s kožo in lasnimi folikli, in je eksprimiran v različnih tumorskih celicah.
Vectibix may have a minor influence on the ability to drive and use machines. 
Zdravilo Vectibix ima lahko blag vpliv na sposobnost vožnje in upravljanja strojev.
If you experience any of these symptoms, you should notify your doctor immediately. 
Če opazite katerega od teh simptomov, morate takoj obvestiti svojega zdravnika.
• headache; dizziness; anxiety. 
• glavobol, omotica, anksioznost.
There are no adequate data from the use of Vectibix in pregnant women. 
Ni zadostnih podatkov o uporabi zdravila Vectibix pri nosečnicah.
It is unknown whether panitumumab is excreted in human breast milk. 
Ni znano, ali se panitumumab pri človeku izloča v materino mleko.
Sodium acetate trihydrate 
Natrijev acetat trihidrat
Do not shake or vigorously agitate the vial. 
Viale ne smete stresati ali močno pretresti.
• cough; dyspnoea (breathing difficulties). 
• kašelj, dispneja (težko dihanje).
Vectibix does not contain any antimicrobial preservative or bacteriostatic agent. 
Zdravilo Vectibix ne vsebuje nobenih antimikrobnih konzervansov ali bakteriostatikov.
Patients with interstitial pneumonitis or pulmonary fibrosis (see section 4.4). 
Bolniki z intersticijskim pnevmonitisom ali pljučno fibrozo (glejte poglavje 4.4).
Monoclonal antibodies are proteins, which specifically recognise and attach (bind) to other unique proteins in the body. 
Monoklonska protitelesa so beljakovine, ki specifično prepoznajo druge edinstvene beljakovine v telesu in se vežejo nanje.
The treatment will usually be given over a period of approximately 60 minutes. 
Dajanje zdravila ponavadi traja približno 60 minut.
• local or widespread rash which may be bumpy (with or without spots), itchy, red or flaky; 
• lokalen ali razširjen izpuščaj, ki je lahko bunčičast (z ali brez peg), srbeč, rdeč ali luskast,
There is no relevant use of Vectibix in the paediatric population in the indication treatment of colorectal cancer. 
Uporaba zdravila Vectibix v pediatrični populaciji za indikacijo zdravljenja kolorektalnega raka ni relevantna.
Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC08 
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe, monoklonska protitelesa, oznaka ATC: L01XC08
The efficacy results from an analysis adjusting for potential bias from unscheduled assessments are shown in the table below. 
Rezultati učinkovitosti iz analize, ki je uporabila korekcijo možne pristranosti zaradi nenačrtovanih ocenjevanj, so prikazani v tabeli spodaj.
Some rashes have been associated with redness, itching and flaking of the skin which can become severe. 
Nekateri izpuščaji so bili povezani z rdečino, srbenjem in luščenjem kože in lahko postanejo hudi.
Binding of panitumumab to EGFR results in internalisation of the receptor, inhibition of cell growth, induction of apoptosis, and decreased interleukin 8 and vascular endothelial growth factor production. 
Vezava panitumumaba na EGFR povzroči internalizacijo receptorja, zavrtje celične rasti, indukcijo apoptoze ter manjše nastajanje interlevkina 8 in žilnega endotelijskega rastnega faktorja.
These toxicities infrequently led to discontinuation of Vectibix or of chemotherapy. 
Ti toksični učinki so redko povzročili prenehanje uporabe zdravila Vectibix ali kemoterapije.
Additional mutations in KRAS and NRAS at exon 3 (codon 59) were subsequently identified (n = 7). 
V nadaljevanju so bile ugotovljene dodatne mutacije KRAS in NRAS v eksonu 3 (kodon 59) (n = 7).
Studies to evaluate the mutagenic and carcinogenic potential of panitumumab have not been performed. 
Študije za oceno mutagenosti in kancerogenosti panitumumaba niso bile izvedene.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 100 mg/5 ml 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 100 mg/5 ml
Do not use Vectibix: 
Ne uporabljajte zdravila Vectibix:
Doses higher than 1,000 mg should be infused over approximately 90 minutes (for handling instructions, see section 6.6). 
Odmerke nad 1.000 mg je treba infundirati približno 90 minut (za navodila za ravnanje glejte poglavje 6.6).
It is important to tell your doctor if you plan to breast-feed. 
Pomembno je, da zdravniku poveste, če nameravate dojiti.
What you need to know before you use Vectibix 
Kaj morate vedeti, preden boste uporabili zdravilo Vectibix
However, infusion reactions were more frequent with cetuximab (13% versus 3%) but electrolyte disturbances were more frequent with panitumumab, especially hypomagnesaemia (29% versus 19%). 
Infuzijske reakcije so bile pogostejše pri cetuksimabu (13 % pri cetuksimabu v primerjavi s 3 % pri panitumumabu), vendar so bile elektrolitske motnje pogostejše pri panitumumabu, še posebej hipomagnezemija (29 % pri panitumumabu v primerjavi z 19 % pri cetuksimabu).
Monitoring as above and repletion as appropriate of these electrolytes is also recommended. 
Priporočljivo je spremljanje, kot je opisano zgoraj, in dodajanje teh elektrolitov, kot je ustrezno.
No overall differences in safety or efficacy were observed in elderly patients (≥ 65 years of age) treated with Vectibix monotherapy. 
V celoti niso ugotovili razlik v varnosti ali učinkovitosti med starejšimi bolniki (starimi ≥ 65 let), ki so prejemali monoterapijo z zdravilom Vectibix.
If Vectibix is used during pregnancy or if the patient becomes pregnant while receiving this medicinal product, she should be advised of the potential risk for loss of the pregnancy or potential hazard to the foetus. 
Če zdravilo Vectibix uporabite med nosečnostjo ali če bolnica med zdravljenjem s tem zdravilom zanosi, jo morate seznaniti z možnim tveganjem za splav in možno nevarnostjo za plod.
A total of 1,010 patients refractory to chemotherapy were randomised 1:1 to receive Vectibix or cetuximab to test whether Vectibix is non-inferior to cetuximab. 
Skupno 1.010 bolnikov, odpornih proti kemoterapiji, so v razmerju 1:1 randomizirali na prejemanje zdravila Vectibix ali cetuksimaba, da bi ugotovili, ali je zdravilo Vectibix neinferiorno cetuksimabu.
If Vectibix is to be used in combination with FOLFOX then it is recommended that mutational status be determined by a laboratory that participates in a RAS External Quality Assurance programme or wild-type status be confirmed in a duplicate test. 
Če je predvidena uporaba zdravila Vectibix v kombinaciji s FOLFOX, je priporočljivo, da mutacijsko stanje določi laboratorij, ki sodeluje v programu Eksterno zagotavljanje kakovosti RAS (RAS External Quality Assurance programme), ali da se stanje divjega tipa potrdi s ponovitvijo testa.
Panitumumab binds onto the EGFR and prevents the cancer cell from receiving the messages it needs for growth and division. 
Panitumumab se veže na EGFR in tako rakavi celici prepreči, da bi sprejela sporočila, potrebna za rast in delitev.
Results from a cross-study comparison indicated that irinotecan-containing regimens (IFL or FOLFIRI) have no effect on the pharmacokinetics of panitumumab. 
Rezultati primerjave v navzkrižni študiji so pokazali, da sheme z irinotekanom (IFL ali FOLFIRI) ne vplivajo na farmakokinetiko panitumumaba.
Results suggest that age (21-88), gender, race, hepatic function, renal function, chemotherapeutic agents, and EGFR membrane staining intensity (1+, 2+, 3+) in tumour cells had no apparent impact on the pharmacokinetics of panitumumab. 
Rezultati kažejo, da starost (21 - 88 let), spol, rasa, delovanje jeter, delovanje ledvic, zdravila za kemoterapijo in intenzivnost membranskega barvanja EGFR (1+, 2+, 3+) na tumorskih celicah nimajo opaznega vpliva na farmakokinetiko panitumumaba.
These events consisted predominantly of rash and dermatitis acneiform and were mostly mild to moderate in severity. 
Ti učinki so obsegali predvsem izpuščaj in akneiformen dermatitis ter so bili večinoma blagi do zmerni.
Patients with a history of, or evidence of, interstitial pneumonitis or pulmonary fibrosis were excluded from clinical studies. 
Bolniki z anamnezo ali znaki intersticijskega pnevmonitisa ali pljučne fibroze so bili izključeni iz kliničnih študij.
Tell your doctor if you use contact lenses and/or have a history of eye problems such as severe dry eye, inflammation of the front part of the eye (cornea) or ulcers involving the front part of the eye. 
Povejte svojemu zdravniku, če uporabljate kontaktne leče in/ali če ste kdaj imeli težave z očmi, kot so zelo suhe oči, vnetje sprednjega dela očesa (roženice) ali razjede, ki so vključevale sprednji del očesa.
Very commonly reported adverse reactions occurring in ≥ 20% of patients were gastrointestinal disorders [diarrhoea (46%), nausea (39%), vomiting (26%), constipation (23%) and abdominal pain (23%)]; general disorders [fatigue (35%), pyrexia (21%)]; metabolism and nutrition disorders [decreased appetite (30%)]; infections and infestations [paronychia (20%)]; and skin and subcutaneous disorders [rash (47%), dermatitis acneiform (39%), pruritus (36%), erythema (33%) and dry skin 
Zelo pogosto opisani neželeni učinki, ki so se pojavili pri ≥ 20 % bolnikov, so bile bolezni prebavil [driska (46 %), navzea (39 %), bruhanje (26 %), zaprtost (23 %) in bolečine v trebuhu (23 %)], splošne težave [utrujenost (35 %), pireksija (21 %)]; presnovne in prehranske motnje [zmanjšan apetit (30 %)]; infekcijske in parazitske bolezni [paronihija (20 %)] ter bolezni kože in podkožja [izpuščaj (47 %), akneiformni dermatitis (39 %), srbenje (36 %), eritem (33 %) in suha koža (21 %)].
In rare cases patients may experience blistering of the skin, mouth, eyes and genitals, which may indicate a severe skin reaction called “Stevens-Johnson syndrome” or blistering of the skin, which may indicate a severe skin reaction called “toxic epidermal necrolysis”. 
V redkih primerih se bolnikom lahko pojavijo mehurji na koži, v ustih, na očeh in spolovilih, ki so lahko znak hude kožne reakcije, imenovane "Stevens-Johnsonov sindrom", ali mehurji na koži, ki so lahko znak hude kožne reakcije, imenovane "toksična epidermalna nekroliza".
Mutational status should be determined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) mutations. 
Mutacijsko stanje mora ugotoviti izkušen laboratorij z uporabo validiranih testnih metod za detekcijo mutacij KRAS (eksoni 2, 3 in 4) in NRAS (eksoni 2, 3 in 4).
Doses higher than 1,000 mg should be infused over approximately 90 minutes. 
Odmerke, večje od 1.000 mg, je treba infundirati približno 90 minut.
Panitumumab treatment was discontinued due to a statistically significant reduction in PFS in patients receiving panitumumab observed in an interim analysis. 
Zdravljenje s panitumumabom so prekinili, ker je bilo na vmesni analizi ugotovljeno statistično značilno skrajšanje PFS med bolniki, ki so dobivali panitumumab.
Clinical efficacy in combination with chemotherapy 
Klinična učinkovitost v kombinaciji s kemoterapijo
Anaphylactic reaction2 
anafilaktična reakcija2
Vectibix has not been tested in pregnant women. 
Zdravilo Vectibix ni preizkušeno pri nosečnicah.
The fatal event occurred after re-exposure following a prior episode of angioedema; both episodes occurred greater than 24 hours after administration (see sections 4.3 and 4.4). 
Bolnik je umrl po ponovni izpostavljenosti zdravilu, ki je sledila predhodnemu angioedemu; obe epizodi sta se pojavili več kot 24 ur po uporabi (glejte poglavji 4.3 in 4.4).
Animal studies have shown reversible effects on the menstrual cycle and reduced female fertility in monkeys (see section 5.3). 
Študije na živalih so pokazale reverzibilne učinke na menstruacijski ciklus in manjšo plodnost opičjih samic (glejte poglavje 5.3).
You may experience skin reactions or severe swelling and tissue damage, if these worsen or become intolerable please tell your doctor or nurse immediately. 
Pojavijo se vam lahko kožne reakcije ali hudo otekanje in poškodba tkiva; če se poslabšajo ali postanejo nevzdržni, nemudoma obvestite zdravnika ali medicinsko sestro.
This medicine contains 3.45 mg sodium (main component of cooking/table salt) in each mL unit. 
To zdravilo vsebuje 3,45 mg natrija (glavne sestavine kuhinjske soli) na ml.
Panitumumab recognises and binds specifically to a protein known as epidermal growth factor receptor (EGFR), which is found on the surface of some cancer cells. 
Panitumumab prepozna in se specifično veže na beljakovino, imenovano receptor za epidermalni rastni dejavnik (EGFR), ki se nahaja na površini nekaterih rakavih celic.
Vectibix is used alone or in combination with other anti-cancer medicines. 
Zdravilo Vectibix se uporablja samostojno ali v kombinaciji z drugimi zdravili proti raku.
Because human IgG is secreted into human milk, panitumumab might also be secreted. 
Ker se v materino mleko izločajo humani IgG, bi se lahko izločal tudi panitumumab.
These can be mild or moderate (likely to occur in approximately 5 out of 100 people who take Vectibix), or severe (likely to occur in 1 out of 100 people who take Vectibix). 
Te reakcije so lahko blage ali zmerne (predvidoma se pojavijo pri približno 5 od 100 bolnikov, ki uporabljajo zdravilo Vectibix), ali hude (predvidoma se pojavijo pri 1 od 100 bolnikov, ki uporabljajo zdravilo Vectibix).
Symptoms may include headache, rashes, itching or hives, flushing, swelling (face, lips, mouth, around the eyes, and throat area), rapid and irregular heartbeat, fast pulse, sweating, nausea, vomiting, dizziness, difficulty breathing or swallowing, or a decrease in blood pressure that may be severe or life-threatening and, very rarely, may lead to death. 
Simptomi lahko vključujejo glavobol, izpuščaje, srbenje ali koprivnico, rdečico, oteklino (obraza, ustnic, ust, predela okoli oči in grla), hitro in neredno bitje srca, hiter srčni utrip, potenje, navzeo, bruhanje, omotico, težave z dihanjem ali s požiranjem, ali znižanje krvnega tlaka, in so lahko hudi ali življensko nevarni in zelo redko tudi smrtni.
The skin rash commonly resembles acne and often involves the face, upper chest and back, but can affect any area of the body. 
Kožni izpuščaj je pogosto podoben aknam, pogosto vključuje obraz, zgornji del prsnega koša in hrbta, lahko pa prizadene kateri koli drug predel na telesu.
• if you have previously had or have evidence of interstitial pneumonitis (swelling of the lungs causing coughing and difficulty breathing) or pulmonary fibrosis (scarring and thickening in the lungs with shortness of breath). 
• če ste kdaj imeli ali imate intersticijsko pljučnico (otekanje pljuč, ki povzroči kašelj in težko dihanje) ali pljučno fibrozo (brazgotinjenje in zadebelitve v pljučih, ki povzročijo kratko sapo),
Fertility studies conducted in female cynomolgus monkeys showed that panitumumab may produce prolonged menstrual cycle and/or amenorrhea and reduced pregnancy rate which occurred at all doses evaluated. 
Študije plodnosti pri samicah opic cynomolgus so pokazale, da lahko panitumumab povzroči podaljšan menstruacijski ciklus in/ali amenorejo ter zmanjša delež nosečnosti, kar se je dogajalo pri vseh ocenjevanih odmerkih.
Patients may be advised to apply moisturiser and sunscreen to face, hands, feet, neck, back and chest every morning during treatment, and to apply the topical steroid to face, hands, feet, neck, back and chest every night during treatment. 
Bolnikom se lahko svetuje, naj v času zdravljenja vsako jutro na obraz, roke, noge, vrat, hrbet in prsi nanesejo vlažilno sredstvo in sredstvo za zaščito pred soncem ter vsak večer na obraz, roke, noge, vrat, hrbet in prsi nanesejo lokalni steroid.
The potential for absorption and harm to the infant after ingestion is unknown. 
Možnost absorpcije in škodljivega delovanja na dojenčka po zaužitju nista znana.
When growth factors (other body proteins) attach to the EGFR, the cancer cell is stimulated to grow and divide. 
Ko se na EGFR vežejo rastni dejavniki (določene druge telesne beljakovine), to rakavo celico spodbudi, da raste in se deli.
Upon disease progression BSC alone patients were eligible to crossover to a companion study and receive Vectibix at a dose of 6 mg/kg given once every two weeks. 
Po napredovanju bolezni so bolniki, ki so prejemali samo BSC, lahko prešli v spremljajočo študijo in dobivali zdravilo Vectibix v odmerku 6 mg/kg enkrat na dva tedna.
You should speak with your doctor before driving or using machines, as some side effects may impair your ability to do so safely. 
Preden vozite ali upravljate stroje, se morate posvetovati z zdravnikom, kajti nekateri neželeni učinki lahko poslabšajo sposobnost za varno izvajanje teh opravil.
Animal studies are insufficient with respect to embryo-foetal development since foetal panitumumab exposure levels were not examined. 
Študije na živalih niso zadostne, kar zadeva razvoj zarodka in ploda, ker raven izpostavljenosti ploda panitumumabu ni raziskana.
Mutant RAS population PFS 
Populacija z mutantnim RAS PFS